iLet Bionic Pancreas System
Type 1 Diabetes
ApprovedCommercial
Key Facts
About Beta Bionics
Beta Bionics is a commercial-stage private company that has developed the iLet Bionic Pancreas, a differentiated automated insulin delivery system. The iLet's key differentiator is its algorithm, which requires only a user's body weight to initialize and then autonomously learns and adapts insulin delivery, eliminating the need for manual carb counting and dose calculations. The system is integrated with leading CGM sensors from Dexcom and Abbott and represents a significant step towards a fully autonomous, decision-free management solution for type 1 diabetes.
View full company profileTherapeutic Areas
Other Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |